GSK-Backed Sitryx Launches With Six Immunometabolism Eggs In Its Basket
GlaxoSmithKline, SV Health Investors and Sofinnova are among the backers of a new Oxford-based biotech which has raised $30m in series A financing and boasts a strong line-up of academic founders. CEO Neil Weir outlines Sitryx's raison d'etre.
You may also be interested in...
Private Company Edition: Iambic, formerly known as Entos, closed a $100m series B venture capital round to advance its AI-discovered therapeutics. Also, Evozyne raised $81m and Acesion brought in €45m in series B rounds, while Mogrify added $10m to bring its series A to $46m.
Lilly is prepared to splash over $600m on an early development deal with ImmuNext on an immunometabolism target which ties the companies together for three years while an antibody is being developed.
Paul Peter Tak recently defected from big pharma to East Coast venture firm Flagship Pioneering. He described the appeal of entrepreneurship in the biotech world and the value of taking the road less traveled when it comes to biomedical R&D.